Investors finally get a glimpse of Rhythm Pharmaceuticals Inc (RYTM) volume hitting the figure of 0.83 million.

On Tuesday, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was -2.64% drop from the session before settling in for the closing price of $64.41. A 52-week range for RYTM has been $35.17 – $68.58.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 189.02% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 40.41%. With a float of $57.21 million, this company’s outstanding shares have now reached $62.39 million.

In an organization with 283 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.44%, operating margin of -204.04%, and the pretax margin is -199.98%.

Rhythm Pharmaceuticals Inc (RYTM) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Rhythm Pharmaceuticals Inc stocks. The insider ownership of Rhythm Pharmaceuticals Inc is 9.97%, while institutional ownership is 94.45%. The most recent insider transaction that took place on Apr 29 ’25, was worth 457,663. In this transaction Chief Human Resources Officer of this company sold 7,031 shares at a rate of $65.09, taking the stock ownership to the 19,209 shares. Before that another transaction happened on Apr 29 ’25, when Company’s EVP, Head of International sold 6,745 for $65.08, making the entire transaction worth $438,946. This insider now owns 37,655 shares in total.

Rhythm Pharmaceuticals Inc (RYTM) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 40.41% per share during the next fiscal year.

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Trading Performance Indicators

You can see what Rhythm Pharmaceuticals Inc (RYTM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.62.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -1.38 in one year’s time.

Technical Analysis of Rhythm Pharmaceuticals Inc (RYTM)

Let’s dig in a bit further. During the last 5-days, its volume was 0.55 million. That was inferior than the volume of 0.63 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 64.39%. Additionally, its Average True Range was 2.91.

During the past 100 days, Rhythm Pharmaceuticals Inc’s (RYTM) raw stochastic average was set at 83.26%, which indicates a significant increase from 52.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.15% in the past 14 days, which was lower than the 49.51% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $56.06, while its 200-day Moving Average is $54.08. However, in the short run, Rhythm Pharmaceuticals Inc’s stock first resistance to watch stands at $64.14. Second resistance stands at $65.57. The third major resistance level sits at $66.90. If the price goes on to break the first support level at $61.38, it is likely to go to the next support level at $60.05. The third support level lies at $58.62 if the price breaches the second support level.

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Key Stats

There are 63,598K outstanding shares of the company, which has a market capitalization of 3.98 billion. As of now, sales total 130,130 K while income totals -260,600 K. Its latest quarter income was 41,830 K while its last quarter net income were -43,330 K.